Ioxilan
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Legal status |
|
Routes of administration |
intravenously |
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | negligible |
Biological half-life | 2 hours |
Excretion | Mostly renal |
Identifiers | |
CAS Number | 107793-72-6 ![]() |
ATC code | V08AB12 (WHO) |
PubChem | CID: 3743 |
ChemSpider | 3612 ![]() |
UNII | A4YJ7J11TG ![]() |
KEGG | D02161 ![]() |
ChEMBL | CHEMBL1201075 ![]() |
Chemical data | |
Formula | C18H24I3N3O8 |
Molecular mass | 791.112 |
|
|
|
|
![]() ![]() |
Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.
<templatestyles src="Asbox/styles.css"></templatestyles>